SUBSCRIBE
SUBSCRIBE

Sudo Biosciences

IN THE PRESS
Press Releases
Sudo Biosciences Announces First Participants Dosed in Phase 1 Trial of Brain-Penetrant Allosteric TYK2 Inhibitor SUDO-550
December 2, 2024
 · 
2 min read
Sudo Biosciences Announces Second Close of Upsized Series B Financing Bringing Total Raised in Round to $147M
February 13, 2024
 · 
6 min read
BioMidwest
Sudo Biosciences Raises $116M Series B Financing to Advance Potential Best-in-Class TYK2 Therapeutics Programs into the Clinic
December 20, 2023
 · 
4 min read
Business
Sudo Biosciences Appoints Imran Babar, Ph.D., as Chief Business Officer
October 10, 2022
 · 
2 min read
Biotech Bay
Sudo Biosciences Raises $37M Series A Financing to Advance Precision TYK2 Therapeutics
September 28, 2022
 · 
3 min read
JOBS